Health Care & Life Sciences » Pharmaceuticals | Samil Pharmaceutical Co. Ltd.

Samil Pharmaceutical Co. Ltd. | Income Statement

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
89,229
85,461
88,136
96,758
92,038
94,600
Cost of Goods Sold (COGS) incl. D&A
53,982
52,193
51,168
55,672
51,879
60,352
Gross Income
35,247
33,268
36,969
41,086
40,159
34,248
SG&A Expense
36,975
42,069
35,084
37,174
38,468
39,554
EBIT
1,979
9,167
1,602
3,618
1,307
5,732
Unusual Expense
372
49
-
-
37
37
Non Operating Income/Expense
1,057
253
295
154
272
53
Interest Expense
1,358
1,381
1,200
1,090
1,771
2,395
Pretax Income
4,198
10,217
1,053
2,668
712
8,135
Income Tax
4,297
972
465
1,782
555
428
Equity in Affiliates
16,425
-
-
-
-
-
Consolidated Net Income
7,930
11,190
588
887
1,267
8,563
Net Income
7,930
11,190
588
887
1,267
8,563
Net Income After Extraordinaries
7,930
11,190
588
887
1,267
8,563
Net Income Available to Common
7,930
11,190
588
887
1,267
8,563
EPS (Basic)
1,469.81
2,098.90
111.13
168.14
239.65
1,621
Basic Shares Outstanding
5
5
5
5
5
5
EPS (Diluted)
1,469.85
2,098.62
111.41
167.88
239.82
1,621.06
Diluted Shares Outstanding
5
5
5
5
5
5
EBITDA
1,550
5,754
4,642
6,765
4,950
2,046
Other Operating Expense
251
366
283
294
384
425
Non-Operating Interest Income
568
633
356
294
62
82

About Samil Pharmaceutical Co.

View Profile
Address
155 Hyoryeong-ro
Seoul SL 06666
Korea, Republic Of
Employees -
Website http://www.samil-pharm.com
Updated 07/08/2019
Samil Pharmaceutical Co., Ltd. engages in the development and manufacture of pharmaceutical products. Its products include CNS Drugs, Ophthalmic Drugs, Respiratory Drugs, Genito-urinary Drugs, Antibiotics Chemotherapeutics, Circulatory Drugs, Gastro-Intestinal Drugs, Agents for Diabetes Mellitus, Hormones, Metabolic Drugs, Disinfectants, Amino Acids, Dental Preparations, Antipyretic, Allergy Drugs, Antihistamines, Analgesic and Anti-inflammatory Agents. The company was founded on October 7, 1947 and is headquartered in Seoul, South Korea.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.